A new treatment for malaria by an old drug (Griseofulvin).

Phase 1

• Conditions: Malaria; Infection - Other infectious diseases

• Registration Number: ACTRN12613000307707
• Lead Sponsor: Macquarie University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-03-20
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Male
• Target Recruitment: 20

Inclusion Criteria

Never had malaria

Exclusion Criteria

Female, planning to have children within 6 months, liver disease, co-morbidity

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Ability of griseofulvin to inhibit the growth of malaria in blood taken from volunteers given the drug. Blood is taken from the volunteers and a portion added to infected red cells in culture. The kinetics of parasite growth is an indication of the ability of the erythrocytes taken from the volunteer to support infection. Parasitaemia is assessed by either fluorescent activated cell sorting or by counting Giemsa-stained thin smears.[Kinetic endpoints. Study to be done over 7 days. Endpoints are Days 1 through 7 for the malaria inhibition.];Pharmacokinetic analysis of griseofulvin in red cells.[Red cells will be taken each day for the 5 days of the trial and griseofulvin will be measured. ];Cliinical chemistry and haematology after for the two trial regimen.[Days 1, 7 and 14]

Secondary Outcome Measures

Name	Time	Method
/A[N/A]